Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.44 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.40 |
| ▸ | MPO | P05164 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 3/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.36 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23014804 | 0.88 | TAAR1 (0.46) | TAAR1LIPGAOC3L3MBTL1MPO | |
| SCHEMBL2584935 | 0.82 | LIPG (0.58) | TAAR1LIPGAOC3MPOTDP1 | |
| SCHEMBL19540033 | 0.82 | LIPG (0.58) | TAAR1LIPGAOC3MPOTDP1 | |
| SCHEMBL2241863 | 0.82 | LIPG (0.58) | TAAR1LIPGAOC3MPOTDP1 | |
| SCHEMBL19540031 | 0.82 | LIPG (0.58) | TAAR1LIPGAOC3MPOTDP1 | |
| SCHEMBL7758952 | 0.82 | LIPG (0.58) | TAAR1LIPGAOC3MPOTDP1 | |
| SCHEMBL14402389 | 0.82 | LIPG (0.58) | TAAR1LIPGAOC3MPOTDP1 | |
| SCHEMBL22268936 | 0.81 | TAAR1 (0.44) | TAAR1LIPGL3MBTL1BCHEACHE | |
| SCHEMBL16934156 | 0.80 | LIPG (0.52) | LIPGBCHEACHE | |
| SCHEMBL9168411 | 0.80 | LIPG (0.56) | LIPGBCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220298185-A1 | Nucleoside Prodrugs and Uses Related Thereto | UNIV EMORY (US) | 2022-09-22 | — | — | US | claimed |
| EP-4017499-A1 | NUCLEOSIDE PRODRUGS AND USES RELATED THERETO | Emory University (US) | 2022-06-29 | — | — | EP | claimed |
| WO-2021035214-A1 | NUCLEOSIDE PRODRUGS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2021-02-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298185-A1 | Nucleoside Prodrugs and Uses Related Thereto | PNPO, GSTO1, CYP2C18 | TAAR1 4098/4885LIPG 295/4885AOC3 844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.